Programme

29th October

15.45-16.15. Registration and congress documentation

16.15. Opening
Mariano Barbacid (Fundación Arces), Jesús San Miguel, Ignacio Melero, Jose Luis Pérez Gracia, Pedro Berraondo

16.30 – 17.00. Keynote Lecture
Chair: Pedro Berraondo. CIMA. Ignacio Melero. CIMA y CUN

Future of cancer immunotherapy: Enhancement or normalization?
Lieping Chen. Yale. USA

17.00 – 18.00. Break

18.00 – 20.40. Exploiting tumor antigenicity
Chair: Juanjo Lasarte. CIMA, Pablo Sarobe. CIMA

18.00. The Yin and Yang of Cancer Immunotherapy Combinations
Daniel Chen. Roche Genentech. USA

18.40. Individualizing Cancer Immunotherapy
Uğur Sahin. Biontech. Germany

19.20. Turning an immunologically cold tumor hot: lessons learned from prostate cancer
James Gulley. NIH. USA

20.00. Radiotherapy and immunotherapy shoulder to shoulder into the fray
Silvia Formenti. Cornell. USA

30th October

09.00 – 11.00. Title: Immunotherapy development: industrial view and pipelines (1)
Chair: Jose Luis Pérez Gracia. CUN, Felipe Calvo. Hospital Gregorio Marañon. Madrid

11.00 – 12.20. Immunotherapy development: industrial view and pipelines (2)
Chair: Luis Paz-Ares. Hospital Universitario Doce de Octubre. Madrid. Spain, Luis Montuenga. CIMA

11.00. Immuno- Oncology Therapeutic Strategy and Pipeline
Philip Gotwals. Novartis. USA

11.20. Building a Next-Generation Immuno-Oncology Pipeline in a Competitive Space: Perspectives from a “New Kid on the Block”
Lazslo Radvanyi. Merck Serono. USA

11.40. A therapeutic strategy to target cold tumors
Eric Borges. Boheringer. Austria

12.00. The Lilly Immunooncology pipeline: enabling rational combinations
Michael Kalos. Lilly. USA

12.20 – 12.40. Round table discussion

12.45-14.00- Lunch break

14.00-14.30. Keynote lecture
Chair: Ignacio Melero. CIMA y CUN, Ruth Vera. Hospital de Navarra

Clinical development of lung cancer immunotherapy
Luis Paz-Ares. Hospital Universitario Doce de Octubre. Madrid. Spain

14.30 – 16.30. Immunotherapy based on evidence
Chair: Ruben Pio. CIMA, Maria Rodriguez. CIMA y CUN

14.30. Targeting immune modulation at the tumour site
Sergio Quezada. UCL. UK

15.10. Anti-cancer immune therapy of melanoma
Mario Szol. Yale. USA

15.50. Exploiting radiotherapy in immunotherapy combinations
Timothy Illidge. The University of Manchester. UK

16.30 – 18.30. Immunotherapy biomarkers, working in the tissue
Chair: Dolores Lozano. CUN, Miguel Idoate. CUN

16.30. Understanding the tumor immune composition using multiplexed quantitative approaches
Kurt Schalper. Yale. USA

17.10. Diagnostics in the era of Cancer Immunotherapy
Priti Hegde. Roche Genentech. USA

17.50. Rethinking the role of radiotherapy in cancer immunotherapy
Mario Sznol. Yale. USA

18.30. Immunology biomarkers, working in the tissue
Chair: Ruben Pio. CIMA, Maria Rodriguez. CIMA y CUN

18.30. Exploiting new tools to improve immunotherapy
Chair: Cristian Smerdou. CIMA, Rubén Hernández Alcoceba. CIMA

18.30. Identification of immunoreactive microsatellite stable (MSS) colorectal cancer for potential immune interventions
Nicolás J. Llosa. Johns Hopkins. USA

19.10. Deconstructing the T cell Receptor signaling nanomachine
Balbino Alarcón. CBM. Spain

19.50. Viruses and IFN in immunotherapy
Pedro Berraondo. CIMA

21.30. Viral gene therapies
Ramón Alemany. VCN. Spain

21.30. Immunotherapy based on evidence
Chair: Ruben Pio. CIMA, Maria Rodriguez. CIMA y CUN

21.30. Targeting immune modulation at the tumour site
Sergio Quezada. UCL. UK

22.10. Exploiting radiotherapy in immunotherapy combinations
Timothy Illidge. The University of Manchester. UK

22.50. Exploiting new tools to improve immunotherapy
Chair: Cristian Smerdou. CIMA, Rubén Hernández Alcoceba. CIMA

31st October

09.00 – 11.00. TNFR costimulation in action
Chair: David Escors. Navarrabiomed. Spain, Fernando Pastor. CIMA

09.00. CD40 stimulation: the rules of a complex game
Ann White. UCB Celltech. UK

09.40. Moving forward CD137-based immunotherapies
Ignacio Melero. CIMA y CUN

10.20 GITR and 4-IBB in chronic viral infection: implications for cancer therapy
Tania Watts. University of Toronto. Canada

11.00 – 11.30. Coffee break

11.30. Genetics and genetic intervention for better immunotherapies
Chair: Cristian Smerdou. CIMA, Rubén Hernández Alcoceba. CIMA

11.30. Targeting immune modulation at the tumour site
Sergio Quezada. UCL. UK

12.10. Anti-cancer immune therapy of melanoma
Mario Szol. Yale. USA

12.50. Exploiting radiotherapy in immunotherapy combinations
Timothy Illidge. The University of Manchester. UK

14.10 – 15.30. Lunch break

15.30 – 17.40. Exploiting new tools to improve immunotherapy
Chair: Susana Inogés. CUN, Ignacio Gil Bazo. CUN

15.30. Complement in cancer immunotherapy
Rubén Pio. CIMA. Spain

16.10. Patient-derived tumor models for immunotherapy development
Miguel Sanmamed. Yale. USA

17.00. Identifying T cells specific against cancer
Alena Gros. Vall d’Hebron. Spain
International Symposium: “Trailblazing in cancer Immunotherapy”

OCTOBER, 29th-31st

Fundación Ramón Areces

VENUE
Modern art museum. University of Navarra. Pamplona, Spain

SYMPOSIUM COORDINATORS
Dr. Ignacio Melero
Dr. Pedro Berraondo
Dr. Jose Luis Pérez Gracia

ORGANIZERS
Fundación para la Investigación Médica Aplicada
Clínica Universidad de Navarra

CONTACT
simposioareces@unav.es

REGISTRATIONS
simposioareces2017.viajesarga.com